Indication
Enterobacteriaceae Infections
4 clinical trials
5 products
Clinical trial
Piperacillin Tazobactam Versus Meropenem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae- a Non-inferiority Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2026-01-01
Product
Piperacillin/tazobactamProduct
MeropenemClinical trial
PipEracillin/Tazobactam vs mERoPENem for Treatment of AmpC-producing Bloodstream Infections: an Extension of the Original PETERPEN TrialStatus: , Estimated PCD: 2028-04-15
Product
Piperacillin / TazobactamClinical trial
Antimicrobial Therapy for Ventilator-associated Pneumonia Among Patients Colonized With Extended-spectrum Beta-lactamase-producing Enterobacteriaceae : Efficacy of a Strategy Using Piperacillin-tazobactam as Empirical Treatment.Status: Recruiting, Estimated PCD: 2024-08-01
Product
Piperacillin-tazobactamClinical trial
A Phase II Randomized Trial to Evaluate the Impact of Fecal Microbiota Transplantation Using the Penn Microbiome Therapy Products on Recipient and Environmental Colonization With Multidrug-Resistant OrganismsStatus: Not yet recruiting, Estimated PCD: 2026-01-01
Product
PMT